Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

[Update on current care guidelines: management of adult obesity].

Suomalaisen Lääkäriseuran Duodecimin; Suomen Lihavuustutkijat RY:n Asettama Työryhmä.

Duodecim. 2011;127(7):730-1. Review. Finnish.

PMID:
21553508
2.

Intensive lifestyle intervention combined with the choice of pharmacotherapy improves weight loss and cardiac risk factors in the obese.

Frost G, Lyons F, Bovill-Taylor C, Carter L, Stuttard J, Dornhorst A.

J Hum Nutr Diet. 2002 Aug;15(4):287-95; quiz 297-9.

PMID:
12153502
3.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

4.

Treatment modalities of obesity: what fits whom?

Hainer V, Toplak H, Mitrakou A.

Diabetes Care. 2008 Feb;31 Suppl 2:S269-77. doi: 10.2337/dc08-s265. Review.

PMID:
18227496
5.

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

Diabetes Obes Metab. 2005 Nov;7(6):699-708.

PMID:
16219013
6.

Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.

Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.

Diabetes Care. 2007 Jan;30(1):27-32.

PMID:
17192328
7.

Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?

Aydin N, Topsever P, Kaya A, Karasakal M, Duman C, Dağar A.

Tohoku J Exp Med. 2004 Mar;202(3):173-80.

8.

Office-based strategies for the management of obesity.

Rao G.

Am Fam Physician. 2010 Jun 15;81(12):1449-56 ; quiz 1429. Review.

9.

[A practicing physician's view on obesity].

Juhász A, Katona E, Csongrádi E, Paragh G.

Orv Hetil. 2006 Apr 2;147(13):579-90. Review. Hungarian.

PMID:
16623440
10.

Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.

MacLaughlin HL, Cook SA, Kariyawasam D, Roseke M, van Niekerk M, Macdougall IC.

Am J Kidney Dis. 2010 Jan;55(1):69-76. doi: 10.1053/j.ajkd.2009.09.011. Epub 2009 Nov 17.

PMID:
19926371
11.

Obesity - an epidemic of the twenty-first century: an update for psychiatrists.

Holt RI.

J Psychopharmacol. 2005 Nov;19(6 Suppl):6-15. Review.

PMID:
16280333
12.

A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease.

Cook SA, MacLaughlin H, Macdougall IC.

Nephrol Dial Transplant. 2008 Jan;23(1):263-8. Epub 2007 Oct 31.

PMID:
17977872
13.

How can primary care providers manage pediatric obesity in the real world?

Hopkins KF, Decristofaro C, Elliott L.

J Am Acad Nurse Pract. 2011 Jun;23(6):278-88. doi: 10.1111/j.1745-7599.2011.00614.x. Epub 2011 Apr 27. Review.

PMID:
21649770
14.

Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.

Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B.

Metabolism. 2009 Jul;58(7):946-53. doi: 10.1016/j.metabol.2009.02.031.

PMID:
19409578
15.

[New therapeutic options in obesity].

Heufelder AE.

MMW Fortschr Med. 2003 Oct 16;145(42):35-9. Review. German.

PMID:
14655442
16.

[Obesity].

Hauner H.

Med Klin (Munich). 2009 Nov 15;104(11):851-66. doi: 10.1007/s00063-009-1182-8. German.

PMID:
19916075
17.

Assessment and management of the obese adult female: a clinical update for providers.

Salazar SS.

J Midwifery Womens Health. 2006 May-Jun;51(3):202-7. Review.

PMID:
16647672
18.

The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.

Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, So WY, Ma RC, Ozaki R, Woo J, Cockram CS, Chan JC.

Arch Intern Med. 2002 Nov 25;162(21):2428-35.

PMID:
12437401
19.

The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.

Nelson RH, Miles JM.

Expert Opin Pharmacother. 2005 Nov;6(14):2483-91. Review.

PMID:
16259579
20.

Weight management and current options in pharmacotherapy: orlistat and sibutramine.

Leung WY, Thomas GN, Chan JC, Tomlinson B.

Clin Ther. 2003 Jan;25(1):58-80. Review.

PMID:
12637112

Supplemental Content

Support Center